Navigation Links
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference

FRANKLIN, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetes management company, announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the RedChip Small-Cap Investor Conference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm Eastern Standard Time). The conference will be held at the Four Seasons Resort in Scottsdale, Arizona. A live video webcast of the presentation will be available on the RedChip Small-Cap Investor Conference website, A replay of the webcast and the corresponding presentation will be available on Echo Therapeutics' website shortly following the live presentation.

About Echo Therapeutics

Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and diabetes management company leveraging its expertise in transdermal science to develop and commercialize non-invasive specialty pharmaceutical products and medical devices. Echo's Symphony(TM) CTGM System is a next generation needle- free, wireless, continuous transdermal glucose monitoring (CTGM) system for diabetes home use and emerging hospital critical care markets. Symphony is designed to provide on-demand glucose data conveniently, continuously and cost-effectively. Symphony incorporates Echo's patented feedback mechanism for optimal skin permeation control and its continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings. Echo is also marshalling the potential of its patented AzoneTS(TM) transdermal drug delivery technology to build an extensive pipeline of advanced topical reformulations of FDA-approved products in accordance with the FDA's Section 505(b)(2) guidelines. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead AzoneTS-based product candidate, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's development plans, objectives, expectations and intentions, including, without limitation, statements regarding the Company's Symphony and AzoneTS product candidates. Factors that could adversely affect Echo's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:

Patrick T. Mooney, M.D.

Chairman & CEO

Echo Therapeutics


Lilian Stern

Stern Investor Relations


SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
2. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Taligen Therapeutics Secures Series B Financing
5. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
9. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):